Showing results (1031-1040 of 1,256) with videos related to

Sort By:
Pageof 126
China CDC Weekly|May 4, 2023
Analysis of Knowledge Level and Use of Antiretroviral Pre-Exposure and Post-Exposure Prophylaxis Among MSM - China, 2019-2022Jiahuan Guo, Wenting Kang, Tongtong Liu, et al.
China CDC Weekly|April 3, 2023
Asymptomatic Norovirus Infection Among Children in Kindergartens and Primary Schools - Beijing Municipality, China, 2021Qingrui Wu, Xiuxia Wei, Jianjun Zhang, et al.
China CDC Weekly|April 3, 2023
Analysis of the Practice of Community-Based Self-Sampling and Its Implication on Prevention and Control of Infectious Diseases - Fengtai District, Beijing Municipality, China, 2022Yaping Wang, Shugang Li, Hao Wu, et al.
China CDC Weekly|April 3, 2023
Confronting COVID-19 and Prioritizing Aging PopulationBinbin Su, Yannan Luo, Yaohua Tian, et al.
China CDC Weekly|April 3, 2023
Trends of SARS-CoV-2 Infection Among Couriers in Risky Business After the Optimization of Prevention and Control Measures - China, December 2022 to January 2023Yu Wu, Fan Ding, Jue Liu, et al.
China CDC Weekly|April 3, 2023
Trends of SARS-CoV-2 Infection in Sentinel Community-Based Surveillance After the Optimization of Prevention and Control Measures - China, December 2022-January 2023Jue Liu, Fan Ding, Yu Wu, et al.
China CDC Weekly|April 3, 2023
Epidemic Features of COVID-19 and Potential Impact of Hospital Strain During the Omicron Wave - Australia, 2022Jingli Yang, Hannah McClymont, Liping Wang, et al.
China CDC Weekly|April 3, 2023
SARS-CoV-2 Surveillance Through China Influenza Surveillance Information System - China, December 1, 2022 to February 12, 2023Xiaoxu Zeng, Yiran Xie, Xiaokun Yang, et al.
China CDC Weekly|April 3, 2023
A Retrospective Modeling Study of the Targeted Non-Pharmaceutical Interventions During the Xinfadi Outbreak in the Early Stage of the COVID-19 Pandemic - Beijing, China, 2020Yan Wang, Kaiyuan Sun, Yang Pan, et al.
China CDC Weekly|April 3, 2023
Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 - China, 2020-2021Xinhua Chen, Xufang Bai, Xinghui Chen, et al.
Pageof 126